89bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 70
- Market Cap
- $968M
- Website
- http://www.89bio.com
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Phase 3
Recruiting
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
- Interventions
- Biological: PegozaferminDrug: Placebo
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 762
- Registration Number
- NCT06419374
- Locations
- 🇨🇳
89bio Clinical Study Site, Kaohsiung, Taiwan
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Phase 3
Recruiting
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) with Fibrosis
- Interventions
- Biological: PegozaferminOther: Placebo
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 1050
- Registration Number
- NCT06318169
- Locations
- 🇬🇧
89bio Clinical Study Site, York, United Kingdom
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia
Phase 3
Recruiting
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: PegozaferminDrug: Placebo
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT05852431
- Locations
- 🇬🇧
89bio Clinical Study Site, Cardiff, United Kingdom
🇵🇷89Bio Clinical Study Site, San Juan, Puerto Rico
🇱🇻89bio Clinical Trial Site, Riga, Latvia
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
Phase 1
Completed
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: BIO89-100
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05022693
- Locations
- 🇺🇸
89bio Clinical Study Site, Chandler, Arizona, United States
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
Phase 2
Active, not recruiting
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: PlaceboDrug: BIO89-100
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT04929483
- Locations
- 🇵🇷
89bio Clinical Study Site, San Juan, Puerto Rico
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
Phase 2
Completed
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: PegozaferminDrug: Placebo
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT04541186
- Locations
- 🇵🇱
89Bio Clinical Study Site, Toruń, Poland
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
Phase 1
Completed
- Conditions
- NASH
- Interventions
- Drug: PegozaferminOther: Placebo
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT04048135
- Locations
- 🇵🇷
89bio Clinical Study Site, San Juan, Puerto Rico
© Copyright 2025. All Rights Reserved by MedPath